Cizzle Biotechnology Holdings（E7F0）株式概要Cizzle Biotechnology Holdings Plcはその子会社とともに、英国で肺がんの早期発見のためのCIZ1Bがんバイオマーカーの免疫測定検査を開発している。 詳細E7F0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬過去5年間の収益は年間8.6%増加しました。 リスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きいマイナスの株主資本 収益が 100 万ドル未満 ( £0 )意味のある時価総額がありません ( €14M )すべてのリスクチェックを見るE7F0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.029該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m25k2016201920222025202620282031Revenue UK£1.0Earnings UK£0.2AdvancedSet Fair ValueView all narrativesCizzle Biotechnology Holdings Plc 競合他社RespiratoriusSymbol: DB:HF00Market cap: €17.8mBiomark DiagnosticsSymbol: DB:20BMarket cap: €36.8mGenetic AnalysisSymbol: DB:8V8Market cap: €42.7m2investSymbol: DB:2INVMarket cap: €45.8m価格と性能株価の高値、安値、推移の概要Cizzle Biotechnology Holdings過去の株価現在の株価UK£0.02952週高値UK£0.0452週安値UK£0.013ベータ0.00301ヶ月の変化43.90%3ヶ月変化110.71%1年変化51.28%3年間の変化13.46%5年間の変化-53.17%IPOからの変化-54.62%最新ニュースお知らせ • May 21Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United KingdomBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 02Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in fundingCizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.お知らせ • Feb 24Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker TestCizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales.お知らせ • Feb 06Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer BiomarkerCizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches.お知らせ • Jun 07Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom最新情報をもっと見るRecent updatesお知らせ • May 21Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United KingdomBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 02Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in fundingCizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.お知らせ • Feb 24Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker TestCizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales.お知らせ • Feb 06Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer BiomarkerCizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches.お知らせ • Jun 07Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdomお知らせ • May 21Cizzle Biotechnology Holdings Plc announced that it has received £0.15 million in fundingCizzle Biotechnology Holdings Plc announced that it has completed a private placement and issued Zero Coupon Convertible loan Notes for aggregate gross proceeds of £150,000 on May 20, 2025. The Note can be converted at any time during its 24 month term into new ordinary shares in the Company at a price of £0.014 per share. The transaction included participation from existing investor Frazer Lang.お知らせ • Mar 25Cizzle Biotechnology Holdings Plc Announces Board and Committee ChangesCizzle Biotechnology Holdings Plc announced the appointment of Edwin Matthew (Matt) Bower as a Non-Executive Director ("NED") of the Company with immediate effect. Matt Bower is an experienced company executive and adviser with a track record as a director and secretary of private equity backed and listed companies, across a broad range of company and technology related activities. He is engaged as a strategic advisor and mentor to the board of directors of a number of high growth trading and technology companies, and a director of a number of private companies. Matt will sit on both the Company's audit and remuneration committees, alongside the Company's independent Non-Executive Director, John Treacy,replacing Prof Dawn Coverley who recently moved from her role as a NED to Chief Scientific Officer, as announced on 2 January 2025. Matt isa Director of Makabo Limited ("Makabo"), a strategic consultancy and board advisory business.お知らせ • Jan 03Cizzle Biotechnology Holdings plc Provides Update on Launch of CIZ1B Biomarker AssayCizzle Biotechnology Holdings plc announced successful completion of the technical programme which confirms that the most cost-effective and scalable version of the CIZ1B biomarker assay for CLIA accreditation is an ELISA. The rigorous quality control programme undertaken has been able to demonstrate equivalence with initial manual laboratory tests and with the BioTechne ProteinSimple capillary Western system. Results have shown sensitivity equivalent to published CIZ1B lung cancer studies, and an ability to correctly identify people with lung cancer with few false negative results. This is another major step in demonstrating that the Company's lung cancer blood test is both cost effective and a commercially scalable global solution to reduce premature cancer deaths and improve survival rates and quality of life for cancer patients.New Risk • Oct 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.07m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€9.07m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.9% increase in shares outstanding).Board Change • Sep 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 05Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United KingdomBoard Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$7.92m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).お知らせ • Apr 12Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct Listingお知らせ • Mar 27Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct ListingNew Risk • Sep 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£768k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£768k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€8.82m market cap, or US$9.33m). Minor Risk Shareholders have been diluted in the past year (7.1% increase in shares outstanding).お知らせ • Jun 13Cizzle Biotechnology Holdings Plc announced that it has received £0.35 million in fundingCizzle Biotechnology Holdings Plc announced that it has raised 16,666,667 common shares at a price of £0.021 for the gross proceeds of £0.35 million on June 12, 2023. The transaction will include participation from new and existing investors.お知らせ • Jun 06Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United KingdomBoard Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Chief Scientific Officer & Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元E7F0DE BiotechsDE 市場7D-18.1%-0.2%3.2%1Y51.3%-12.1%2.5%株主還元を見る業界別リターン: E7F0過去 1 年間で-12.1 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: E7F0過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is E7F0's price volatile compared to industry and market?E7F0 volatilityE7F0 Average Weekly Movement19.9%Biotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: E7F0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: E7F0の weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a4n/awww.cizzlebiotechnology.comCizzle Biotechnology Holdings Plcはその子会社とともに、英国で肺がんの早期発見のためのCIZ1Bがんバイオマーカーのイムノアッセイ検査を開発している。同社は以前はCizzle Biotechnology Limitedとして知られていたが、2021年5月にCizzle Biotechnology Holdings Plcに社名を変更した。Cizzle Biotechnology Holdings Plcの本社は英国ロンドンにある。もっと見るCizzle Biotechnology Holdings Plc 基礎のまとめCizzle Biotechnology Holdings の収益と売上を時価総額と比較するとどうか。E7F0 基礎統計学時価総額€14.27m収益（TTM）-€800.18k売上高(TTM)n/a0.0xP/Sレシオ-17.8xPER（株価収益率E7F0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計E7F0 損益計算書（TTM）収益UK£0売上原価UK£0売上総利益UK£0その他の費用UK£691.00k収益-UK£691.00k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0016グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%E7F0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 16:07終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cizzle Biotechnology Holdings Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Michael FosterHardman & Co.Martin HallHardman & Co.
お知らせ • May 21Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United Kingdom
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 02Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in fundingCizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.
お知らせ • Feb 24Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker TestCizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales.
お知らせ • Feb 06Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer BiomarkerCizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches.
お知らせ • Jun 07Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom
お知らせ • May 21Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 16, 2026. Location: the offices of shakespeare martineau llp, c o ampa holdings llp, level 19, the shard, 32 london bridge street, se1 9sg, london United Kingdom
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director John Treacy was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 02Cizzle Biotechnology Holdings Plc announced that it expects to receive £0.25 million in fundingCizzle Biotechnology Holdings Plc announced a private placement of unsecured convertible loan notes for gross proceeds of up to £250,000 on April 2, 2026. The transaction will include participation from existing investor Frazer Lang. The notes will be draw down as to £100,000 on May 1, 2026, £100,000 on June 1, 2026, and £50,000 on July 1, 2026. The notes will now be convertible at £.014 per ordinary share at any time up to October 30, 2026. No interest or fees are payable on the notes. In connection with the transaction, the company has issued warrants to Frazer Lang over 10,000,000 ordinary shares at an exercise price of £0.025, to be exercised within two years from the date of issue, bringing his total warrant holding to 22,500,000 warrants.
お知らせ • Feb 24Cizzle Biotechnology Holdings plc Provides an Update on Progress Towards the Accreditation and Launch of Its Proprietary Test for the Ciz1b Biomarker TestCizzle Biotechnology Holdings Plc provided an update on progress towards the accreditation and launch of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. The Company's North American Licensing partner Cizzle Bio Inc. ("BIO") is now in the final stages of the Clinical Laboratory Improvement Amendments ("CLIA") accreditation process and expect to submit an application for approval in second quarter of 2026. Given the positive progress, BIO and the Company have strengthened their commitment with a new payment schedule which includes a further minimum USD 3.5m advanced royalty schedule to reflect the commencement of sales and long-term growth of the test at scale. BIO and the Company have been working on site, together with BIO's clinical testing partner, Omni Health Diagnostics Inc. ("Omni") in their facility in Richardson, Texas, USA to establish operating procedures ahead of submitting a full validation package for CLIA accreditation. On submission, accreditation is usually immediate unless any clarification is sought. As part of the previously agreed advance exclusivity and royalty fees, BIO has to date paid USD590,000 of the guaranteed advance payments of USD 2.4 million due by 31 December 2026. The Company and BIO have now agreed to a minimum of USD 3.5m of guaranteed further payments over the seven years following an extension of the current agreement in 2031. This will ensure that there are guaranteed payments beyond the initial seven year period of the licence and aligned regular payments after the commercial launch of the test. The new schedule of payments reconfirms the Company will receive the remaining USD 1.81m of the initial advance royalty payments due by 31 December 2026". BIO's strategy is to achieve CLIA accreditation and market launch of the Company's CIZ1B biomarker test with its clinical diagnostics partner Omni in the shortest time possible, thus enabling a roll out campaign across North America. The CLIA accreditation process is necessarily detailed requiring rigorous validation following strict operating procedures. The results generated provide information on analytical accuracy and precision, that together with Omni's own quality assurance processes, provide the basis for submitting the accreditation application. Key personnel from the Company have been working alongside Omni's team in the laboratory in Texas, who expect to complete the testing programme shortly. On submission, accreditation are usually immediate unless any clarification is seeking. Following CLIA accreditation, BIO expects immediate take up based on patient requests for early access to the CIZ1B test. BIO will report when first commercial sales have occurred. Additional Guaranteed Royalties and Advance Royalty Payments The Company has now received payments totalling USD 5.81m from BIO for initial exclusivity fees and advanced royalties as part of guaranteed payments due to the Company totaling USD 2.4 million over the period ending 31 December 2026. A revised payment schedule has been agreed whereby the remaining payments of USD 1.81m of The initial guaranteed advance royalty payments will, as previously reported, be paid before the end of 2026. As noted in the Company's Annual Report for 2024, if these payments are delayed or not received, the Company may need to seek alternative funding. These are the minimum royalties to be paid as part of the Company's licensing agreement with BIO, whereby the Company will receive 10% on gross sales over the initial 7-year period of the agreement which commenced on 18 October 2024. As part of committing to the long-term aim of saving lives through early cancer detection, the Company and BIO have now agreement in 2031, equivalent to a minimum of USD 500,000 per year as part of the ongoing 10% royalty on all sales.
お知らせ • Feb 06Cizzle Biotechnology Holdings plc Announces Patent Applications That Claim Protection for Methods That Measure the Ciz1b Lung Cancer BiomarkerCizzle Biotechnology announced that patent applications that claim protection for methods that measure the CIZ1B lung cancer biomarker have been granted by the Canadian intellectual property office. The Company has a strong patent portfolio and continues to seek additional protection in other key markets globally. In addition to its existing patent coverage in the USA, a further application is likely to be granted by the United States patent and trademark office in due course. The patent 'Use of a fibrinogen capture agent to detect a CIZ1B variant' concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc. ("BIO") for use in North America and the Caribbean and these new patents will strengthen BIO's position in commercialising the Company's innovative and proprietary technology. The discovery and development of the CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company's founder and CSO, and her research team at the University of York. Initially supported by both UK Research and Industry and Charity sector research grants it has been the ambition to translate the laboratory findings into products that benefit future cancer patients in the UK, and elsewhere around the world. Cizzle Biotechnology's patent portfolio and technology know-how enhances the Company's ability to deliver it's global commercial strategy to licence globally its proprietary test for the CIZ1 B biomarker for use in the early detection of lung cancer. The Company's first licence agreement with BIO for North America and the Caribbean, has led to partnerships between BIO and specialist clinical laboratories and hospitals, to enable market penetration that makes the test available to as many clinicians and patients as possible. Cizzle Biotechnology also has been granted patent protection from the European Patent Office and is now focussed on securing partnerships with accredited facilities in the UK and Europe including the NHS. This aligns well with the current NHS cancer plan which aims to dramatically improve cancer survival by increasing the proportion of cancers diagnosed at stages 1 and 2 from half to three-quarters by 2028. This shift towards earlier diagnosis is expected to save 55,000 additional lives per year by 2028. The plan focuses on improving access to diagnosis and treatment, raising awareness of cancer symptoms, and increasing the number of cancers identified through screening, including personalised and risk-stratified approaches.
お知らせ • Jun 07Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom
お知らせ • May 21Cizzle Biotechnology Holdings Plc announced that it has received £0.15 million in fundingCizzle Biotechnology Holdings Plc announced that it has completed a private placement and issued Zero Coupon Convertible loan Notes for aggregate gross proceeds of £150,000 on May 20, 2025. The Note can be converted at any time during its 24 month term into new ordinary shares in the Company at a price of £0.014 per share. The transaction included participation from existing investor Frazer Lang.
お知らせ • Mar 25Cizzle Biotechnology Holdings Plc Announces Board and Committee ChangesCizzle Biotechnology Holdings Plc announced the appointment of Edwin Matthew (Matt) Bower as a Non-Executive Director ("NED") of the Company with immediate effect. Matt Bower is an experienced company executive and adviser with a track record as a director and secretary of private equity backed and listed companies, across a broad range of company and technology related activities. He is engaged as a strategic advisor and mentor to the board of directors of a number of high growth trading and technology companies, and a director of a number of private companies. Matt will sit on both the Company's audit and remuneration committees, alongside the Company's independent Non-Executive Director, John Treacy,replacing Prof Dawn Coverley who recently moved from her role as a NED to Chief Scientific Officer, as announced on 2 January 2025. Matt isa Director of Makabo Limited ("Makabo"), a strategic consultancy and board advisory business.
お知らせ • Jan 03Cizzle Biotechnology Holdings plc Provides Update on Launch of CIZ1B Biomarker AssayCizzle Biotechnology Holdings plc announced successful completion of the technical programme which confirms that the most cost-effective and scalable version of the CIZ1B biomarker assay for CLIA accreditation is an ELISA. The rigorous quality control programme undertaken has been able to demonstrate equivalence with initial manual laboratory tests and with the BioTechne ProteinSimple capillary Western system. Results have shown sensitivity equivalent to published CIZ1B lung cancer studies, and an ability to correctly identify people with lung cancer with few false negative results. This is another major step in demonstrating that the Company's lung cancer blood test is both cost effective and a commercially scalable global solution to reduce premature cancer deaths and improve survival rates and quality of life for cancer patients.
New Risk • Oct 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.07m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€9.07m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (8.9% increase in shares outstanding).
Board Change • Sep 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 05Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 24, 2024. Location: the offices of shakespeare martineau llp, 6th floor, 60 gracechurch street, ec3v 0hr, london United Kingdom
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Founder & Independent Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$7.92m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).
お知らせ • Apr 12Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 27Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million.Cizzle Biotechnology Holdings Plc has filed a Follow-on Equity Offering in the amount of £0.621 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 31,050,000 Price\Range: £0.02 Transaction Features: Subsequent Direct Listing
New Risk • Sep 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£768k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£768k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (€8.82m market cap, or US$9.33m). Minor Risk Shareholders have been diluted in the past year (7.1% increase in shares outstanding).
お知らせ • Jun 13Cizzle Biotechnology Holdings Plc announced that it has received £0.35 million in fundingCizzle Biotechnology Holdings Plc announced that it has raised 16,666,667 common shares at a price of £0.021 for the gross proceeds of £0.35 million on June 12, 2023. The transaction will include participation from new and existing investors.
お知らせ • Jun 06Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023Cizzle Biotechnology Holdings Plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street London United Kingdom
Board Change • Nov 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Chief Scientific Officer & Non-Executive Director Dawn Coverley was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
